

Special Issue

Antituberculosis Drugs

Message from the Guest Editor

Tuberculosis (TB), a disease caused by *Mycobacterium tuberculosis* (Mt), is one of the deadliest infectious diseases. Each year almost 2 million people die worldwide according to estimates from the World Health Organization (WHO). The treatment for tuberculosis is more than 30 years old and includes a multidrug approach during a long period of time (6–9 months). There are several resistant strains of Mt including multidrug (MDR) strains resistant to more than one first line drugs and extremely resistant strains (XDR), resistant to first and second line drugs. These strains have made Mt and TB very difficult to treat and eradicate. This special issue will focus on the biology of Mt, resistance, new targets, drug discovery and development, and clinical trials.

Guest Editor

Prof. Dr. Marcelo J. Nieto

Department of Pharmaceutical Sciences, School of Pharmacy,
Southern Illinois University Edwardsville, Edwardsville, IL 62026-2000,
USA

Deadline for manuscript submissions

closed (31 August 2012)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/1336

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)